This study hopes to improve early detection of ovarian and endometrial cancers. It will determine if women with bloating, abdominal distension, abdominal/pelvic pain, increased urinary frequency and/or early satiety, benefit from earlier surgery after screening by CA-125 ovarian cancer biomarker and transvaginal ultrasound.
Study Type
OBSERVATIONAL
Enrollment
13,600
* CA-125 biomarker blood test at visit 1, day 1. * CA-125 biomarker blood test at visit 2, week 6.
-Transvaginal Ultrasound at visit 1, day 1.
Phone call 6 months after last visit to verify continued health.
West Island Cancer Wellness Centre
Kirkland, Quebec, Canada
ACTIVE_NOT_RECRUITINGAxion 50 plus
Laval, Quebec, Canada
ACTIVE_NOT_RECRUITINGClinique Familiale Pas-A-Pas
Montreal, Quebec, Canada
Proportion of diagnoses in early, curable stage.
To determine whether the provision of fast-track diagnostic evaluation of symptomatic women ≥50 years will result in a higher proportion of ovarian cancer, including high-grade serous cancers (HGSCs), diagnosed in low-volume, completely resectable stage.
Time frame: Up to 3 years
Number of participants with physical morbidity related to the program as a measure of safety and tolerability
To determine the physical morbidity associated with testing symptomatic women for ovarian cancer by CA-125 and transvaginal ultrasound. Participants will complete the DOvE Program Impact Assessment at Visit 1, and the Impact of Program on Patient's Well-being Questionnaire at Visit 3.
Time frame: Up to 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clinique Médicale du Haut-Anjou
Montreal, Quebec, Canada
ACTIVE_NOT_RECRUITINGMcGill University Health Centre, Royal Victoria Hospital
Montreal, Quebec, Canada
RECRUITINGQueen Elizabeth Health Centre
Montreal, Quebec, Canada
RECRUITINGLachine Hospital
Montreal, Quebec, Canada
ACTIVE_NOT_RECRUITINGClinique du Dr. L. Quintal
Saint-Lambert, Quebec, Canada
ACTIVE_NOT_RECRUITING